Care with Zoey is private (self-pay). For medicines prescribed off-label, this page sets out their approval status, where they come from, whether approved alternatives exist in Japan, their status overseas, and the Relief System.
This service is private care, not covered by public health insurance, so you pay the full cost. A doctor sees you and decides whether a medicine suits you before prescribing it, and may decide not to prescribe.
Costs, with tax, are on each treatment page.
Mounjaro (tirzepatide), Rybelsus (semaglutide) and Victoza (liraglutide) are approved in Japan for type 2 diabetes. Prescribing them for obesity or weight management isn’t approved in Japan (off-label use). Wegovy (semaglutide) is approved in Japan for obesity disease.
The partner clinic’s doctors buy them through pharmaceutical wholesalers in Japan.
Medicines with the same active ingredient approved in Japan for obesity disease: semaglutide as Wegovy, and tirzepatide as Zepbound. Liraglutide isn’t approved in Japan for obesity.
GLP-1 and GIP/GLP-1 receptor agonists are approved by the US FDA, the European EMA and others. See each medicine’s prescribing information for details.
Marvelon 28 and Anju 28 are approved in Japan as oral contraceptives (in-label). Yaz is approved in Japan for painful periods, so prescribing it for contraception is off-label. Slinda 28 is approved in Japan as an oral contraceptive (in-label).
The partner clinic’s doctors buy them through pharmaceutical wholesalers in Japan.
Low-dose oral contraceptives such as Marvelon 28 are approved in Japan for contraception.
Drospirenone with ethinylestradiol, and drospirenone on its own, are approved as oral contraceptives by the US FDA, in Europe and elsewhere. See each medicine’s prescribing information for details.
Even when a medicine is used for its approved indication, Japan’s Relief System for Sufferers from Adverse Drug Reactions may not cover a serious side effect. Off-label use isn’t covered.